Immune-Cell-Based Therapy for COVID-19: Current Status

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role in managing COVID-19. Cell therapy has recently emerged as a promising strategy t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yiyuan, Liang, Qinghe, Chen, Fengsheng, Zheng, Jiehuang, Chen, Yan, Chen, Ziye, Li, Ruopeng, Li, Xiaojuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674523/
https://www.ncbi.nlm.nih.gov/pubmed/38005826
http://dx.doi.org/10.3390/v15112148
Descripción
Sumario:Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role in managing COVID-19. Cell therapy has recently emerged as a promising strategy to modulate the immune system, offering immense potential for the treatment of COVID-19 due to its customizability and regenerative capabilities. This review provides an overview of the various subsets of immune cell subsets implicated in the pathogenesis of COVID-19 and a comprehensive summary of the current status of immune cell therapy in COVID-19 treatment.

Ejemplares similares